Results 41 to 50 of about 20,782 (204)

Dolutegravir-Associated Hyperglycemia in a Patient on Highly Active Antiretroviral Therapies

Nigerian Journal of Medicine
Highly active antiretroviral medications have been reported to cause hyperglycaemia in the literature especially the protease inhibitor. We however report a case of dolutegravir-associated hyperglycaemia which is an integrase strand transfer inhibitor.
Abosede Grace Adeyeye, Victor Oladeji Adeyeye   +1 more
doaj   +1 more source

Three-Drug Regimens Containing Integrase Inhibitor Show Good Efficacy and Safety in Treatment-Naive Patients With HIV-1: A Bayesian Analysis

Frontiers in Pharmacology, 2021
Introduction: The extensive utilisation of antiretroviral therapy has greatly improved the survival rates of those infected with human immunodeficiency virus (HIV).
Ke Zhang, Ke Zhang, Yang Zhang, Yang Zhang, Xinchao Liu, Aixin Li, Meixia Gao, Jianhua Hou, Jianhua Hou, Chunxiang Guo, Tong Zhang, Tong Zhang, Hao Wu, Hao Wu, Guanzhi Chen, Xiaojie Huang   +15 more
doaj   +1 more source

Polypharmacy in HIV: Rethinking what counts and why it matters

HIV Medicine, EarlyView.
Abstract Polypharmacy, the concurrent use of multiple medications, presents a growing challenge in HIV care as people living with HIV age and experience earlier onset of age‐related co‐morbidities. However, how polypharmacy is defined and assessed in HIV research remains inconsistent.
Luxsena Sukumaran, Alan Winston, Catia Marzolini, Saye Khoo, Marta Boffito, Nadia Naous, Caroline A. Sabin   +6 more
wiley   +1 more source

Mutations Located outside the Integrase Gene Can Confer Resistance to HIV-1 Integrase Strand Transfer Inhibitors

mBio, 2017
Resistance to the integrase strand transfer inhibitors raltegravir and elvitegravir is often due to well-identified mutations in the integrase gene. However, the situation is less clear for patients who fail dolutegravir treatment.
Isabelle Malet, Frédéric Subra, Charlotte Charpentier, Gilles Collin, Diane Descamps, Vincent Calvez, Anne-Geneviève Marcelin, Olivier Delelis   +7 more
doaj   +1 more source

Treatment with integrase inhibitors alters SARS‐CoV‐2 neutralization levels measured with HIV‐based pseudotypes in people living with HIV [PDF]

, 2023
Erick De La Torre Tarazona, Alba González‐Robles, Almudena Cascajero, Paloma Jiménez, José M. Miró, Sonsoles Sánchez‐Palomino, José Alcamı́, María J. Buzón, Javier García‐Pérez   +8 more
openalex   +1 more source

Temporal network analysis of comorbidities among people with HIV in South Carolina

HIV Medicine, EarlyView.
Abstract Introduction People with HIV experience a high rate of comorbidities that can complicate their health outcomes. Understanding the prevalence, interrelationships and temporal development of these comorbidities is crucial for improving health management and quality of life for people with HIV.
Yunqing Ma, Matthew Lohman, Monique J. Brown, Yichen Li, Xiaoming Li, Bankole Olatosi, Jiajia Zhang   +6 more
wiley   +1 more source

Brief Histories of Retroviral Integration Research and Associated International Conferences

Viruses
The field of retroviral integration research has a long history that started with the provirus hypothesis and subsequent discoveries of the retroviral reverse transcriptase and integrase enzymes.
Duane P. Grandgenett, Alan N. Engelman
doaj   +1 more source

Early treatment regimens achieve sustained virologic remission in infant macaques infected with SIV at birth

Nature Communications, 2022
Neonates and infants infected with HIV generally develop disease rapidly, with early antiretroviral therapy (ART) often failing to achieve a sustained state of ART-free virologic remission.
Xiaolei Wang, Eunice Vincent, Summer Siddiqui, Katherine Turnbull, Hong Lu, Robert Blair, Xueling Wu, Meagan Watkins, Widade Ziani, Jiasheng Shao, Lara A. Doyle-Meyers, Kasi E. Russell-Lodrigue, Rudolf P. Bohm, Ronald S. Veazey, Huanbin Xu   +14 more
doaj   +1 more source

Exploring the impact of baseline and on‐treatment variables on durability of responses to fostemsavir through weeks 96 and 192 in the phase 3 BRIGHTE study

HIV Medicine, EarlyView.
Abstract Objectives The gp120‐directed attachment inhibitor fostemsavir was effective in people with multidrug‐resistant (MDR) HIV‐1 in the BRIGHTE study. Understanding factors associated with virologic response can help clinicians optimize treatment and identify individuals for fostemsavir‐based regimens.
M. Gartland, X. Wang, Q. Liao, B. Li, F. Du, M. Krystal, A. R. Tenorio, A. Pierce, J. R. Castillo‐Mancilla   +8 more
wiley   +1 more source

Natural variation of HIV-1 group M integrase: Implications for a new class of antiretroviral inhibitors

Retrovirology, 2008
HIV-1 integrase is the third enzymatic target of antiretroviral (ARV) therapy. However, few data have been published on the distribution of naturally occurring amino acid variation in this enzyme.
Gifford Robert J, Zioni Rafael, Kiuchi Mark, Liu Tommy F, Rhee Soo-Yon, Holmes Susan P, Shafer Robert W   +6 more
doaj   +1 more source